Recently, a new approach using activators of peroxisome proliferator-activated receptor gamma (PPARγ) to inhibit proliferation and increase cell death in breast cancer cell lines has given hope to the development of a new class of anticancer drugs [27]. Here, PPARG is linked to breast cancer.